Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received a consensus recommendation of “Buy” from the eleven ratings firms that are covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $11.05.
AUPH has been the topic of a number of recent research reports. Zacks Investment Research upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. BidaskClub upgraded Aurinia Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, January 5th. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price (up from $10.00) on shares of Aurinia Pharmaceuticals in a report on Monday, October 30th. Cantor Fitzgerald reiterated a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, October 23rd. Finally, Royal Bank of Canada initiated coverage on Aurinia Pharmaceuticals in a report on Thursday. They issued an “outperform” rating and a $9.00 target price on the stock.
A number of large investors have recently modified their holdings of the business. FMR LLC lifted its stake in Aurinia Pharmaceuticals by 0.3% during the 2nd quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after acquiring an additional 19,200 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Aurinia Pharmaceuticals by 357.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after acquiring an additional 684,816 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Aurinia Pharmaceuticals by 1.8% during the 3rd quarter. Alyeska Investment Group L.P. now owns 681,517 shares of the biotechnology company’s stock valued at $4,273,000 after acquiring an additional 12,171 shares in the last quarter. Balyasny Asset Management LLC lifted its stake in Aurinia Pharmaceuticals by 66.7% during the 2nd quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after acquiring an additional 200,000 shares in the last quarter. Finally, AWM Investment Company Inc. lifted its stake in Aurinia Pharmaceuticals by 17.5% during the 2nd quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after acquiring an additional 52,500 shares in the last quarter. Institutional investors and hedge funds own 28.08% of the company’s stock.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The company’s quarterly revenue was up .0% on a year-over-year basis. sell-side analysts anticipate that Aurinia Pharmaceuticals will post -1.08 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Analysts Set Aurinia Pharmaceuticals Inc (AUPH) Price Target at $11.39” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.com-unik.info/2018/02/09/analysts-set-aurinia-pharmaceuticals-inc-auph-price-target-at-11-39.html.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.